Chou et al. detected that simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increased therapeutic efficacy against GBM multiforme with significant reductions in several signaling proteins important for tumor cell proliferation and invasion [84]. Here, EGFR is linked to neoplasm.